Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Enerflex Q4 EPS $(0.68), Sales $689.80M

Enerflex (NYSE:EFXT) reported quarterly losses of $(0.68) per share. The company reported $689.80 million in sales this quarter.

byMichael Horton

March 1, 2023

1 minute read

Enerflex (NYSE:EFXT) reported quarterly losses of $(0.68) per share. The company reported $689.80 million in sales this quarter.

Morgan Stanley Maintains Overweight on New Relic, Lowers Price Target to $64

By Benzinga Newsdesk

May 13, 9:00 AM

Morgan Stanley analyst Sanjit Singh maintains New Relic (NYSE:NEWR) with a Overweight and lowers the price target from $138 to $64.

NEWR

Helius Medical’s Neuromodulation Stimulator Nabs FDA Breakthrough Tag

By Vandana Singh

August 17, 8:00 AM

The FDA has granted Breakthrough Device Designation to Helius Medical Technologies Inc’s (NASDAQ:HSDT) PoNS device. Related content: Benzinga’s Full FDA Calendar. The designation…

HSDT

Benchmark Reiterates Buy on Papa John’s International, Maintains $95 Price Target

By Benzinga Newsdesk

February 27, 9:42 AM

Benchmark analyst Todd Brooks reiterates Papa John's International (NASDAQ:PZZA) with a Buy and maintains $95 price target.

PZZA

Bharat Biotech MD Says Pfizer, Moderna Vaccines Wouldn’t Have Gotten Nod Had They Done Phase 3 Trials In 2nd Wave

By Benzinga Newsdesk

September 1, 12:11 PM

-Reuters

BNTX

Enerflex Q4 EPS $(0.68), Sales $689.80M

Related Posts

Morgan Stanley Maintains Overweight on New Relic, Lowers Price Target to $64

Helius Medical’s Neuromodulation Stimulator Nabs FDA Breakthrough Tag

Benchmark Reiterates Buy on Papa John’s International, Maintains $95 Price Target

Bharat Biotech MD Says Pfizer, Moderna Vaccines Wouldn’t Have Gotten Nod Had They Done Phase 3 Trials In 2nd Wave